XTX Topco Ltd Sells 40,545 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL)

XTX Topco Ltd reduced its position in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 36.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 70,174 shares of the company’s stock after selling 40,545 shares during the quarter. XTX Topco Ltd’s holdings in Lyell Immunopharma were worth $102,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Invenomic Capital Management LP acquired a new position in shares of Lyell Immunopharma during the 4th quarter worth about $1,448,000. Susquehanna Fundamental Investments LLC acquired a new position in Lyell Immunopharma during the first quarter worth approximately $191,000. Acadian Asset Management LLC bought a new stake in Lyell Immunopharma in the first quarter valued at approximately $173,000. TD Asset Management Inc lifted its position in shares of Lyell Immunopharma by 4.2% in the second quarter. TD Asset Management Inc now owns 1,004,642 shares of the company’s stock valued at $1,457,000 after buying an additional 40,800 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new position in shares of Lyell Immunopharma during the 1st quarter worth approximately $64,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Lyell Immunopharma Trading Down 7.2 %

Lyell Immunopharma stock opened at $1.28 on Wednesday. The company has a market capitalization of $326.32 million, a price-to-earnings ratio of -1.42 and a beta of -0.53. The stock’s 50 day moving average is $1.41 and its 200-day moving average is $1.93. Lyell Immunopharma, Inc. has a 12 month low of $1.09 and a 12 month high of $3.26.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.02. The firm had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative return on equity of 33.35% and a negative net margin of 389,368.50%. As a group, equities research analysts predict that Lyell Immunopharma, Inc. will post -0.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Bank of America dropped their price target on Lyell Immunopharma from $9.00 to $6.00 and set a “buy” rating on the stock in a research note on Thursday, June 27th. HC Wainwright reissued a “neutral” rating and issued a $1.00 price objective on shares of Lyell Immunopharma in a research report on Monday, August 19th.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.